New French study on Covid-19 drug ‘provides hope’

Front cover of the specialist medical journal The Lancet Rheumatology. A new study has found that a drug named “anakinra” has shown “encouraging results” and “provides hope” in treating patients with severe forms of Covid-19.
The study was published this week in specialist medical journal The Lancet Rheumatology

A French study on a drug named “anakinra” has shown “encouraging results” and “provides hope” in treating patients with severe forms of Covid-19.

The study suggests that the drug, which is currently used for rheumatic conditions, appears to reduce the risk of death from Covid-19, and means patients with severe forms of the illness are less likely to need a ventilator.

The study was completed by rheumatologist Dr. Thomas Huet and the team at the Groupe Hospitalier Paris Saint-Joseph (14th arrondissement, Paris), and published on May 28 in specialist medical journal The Lancet Rheumatology.

The team injected 52 severe Covid-19 patients with anakinra for a period ...

To read the remaining 85% of this article, you need to either

Subscribe now to The Connexion and benefit from access to our archived articles since 2006

Print + Digital 3 month subscription

Pay every three months. Our most flexible subscription.

Automatic renewal, cancel anytime

Print + Digital 1 year subscription

1 year of great reading in print and online

Automatic renewal, cancel anytime

Digital 1 year subscription (Our best value offer)

1 year of great reading online *no paper*

Automatic renewal, cancel anytime

Digital 3 month subscription

3 months of great reading online *no paper*

Automatic renewal, cancel anytime

More articles from French news
More articles from Connexion France
Other articles that may interest you